1
|
Patel RD, Raval MK, Pethani TM, Waghela BN, Shukla RH, Buch PR, Vadalia JM, Sharma TP, Airao VA. RP-HPLC METHOD DEVELOPMENT, VALIDATION, AND ITS PHARMACOKINETIC APPLICABILITY IN PRECLINICAL EVALUATION OF RHEIN TREATED WITH NOVEL DIACEREIN EUTECTICS. Biomed Chromatogr 2022; 36:e5465. [PMID: 35904137 DOI: 10.1002/bmc.5465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 06/11/2022] [Accepted: 07/25/2022] [Indexed: 11/07/2022]
Abstract
The current study represents the bio-analytical method for the estimation of Rhein (Rh, an active metabolite of Diacerein (DIA)) in rats treated with novel DIA eutectics to investigate the pharmacokinetics of DIA. A simple protein precipitation technique was used to extract Rh and internal standard (IS), p-aminobenzoic acid, and injected into a Phenomenex Gemini C18 column. The separation was achieved by gradient elution comprising of ammonium acetate (10 mM; pH 3.0) and acetonitrile in 18 min of run time at a flow rate of 0.8 mL/min with the retention time of 11.8 min (Rh) and 5.9 min (IS). The results revealed that the proposed method was linear over the range of 200-20,000 ng/mL (r2 > 0.9988) of Rh and proved to be precise and accurate. The method was fully validated as per the USFDA guideline and the pharmacokinetic study in rats was performed for Rh following oral administration of the pure DIA and newly developed eutectics. Therefore, the present method could be used to estimate DIA to illustrate the comparative pharmacokinetic analysis. This can be also applied to its related multi-component formulations for future study.
Collapse
Affiliation(s)
- Rajeshri D Patel
- School of Pharmaceutical Sciences, Atmiya University, Rajkot, Gujarat, India
| | - Mihir K Raval
- Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India
| | - Trupesh M Pethani
- Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India
| | - Bhargav N Waghela
- Department of Microbiology, Atmiya University, Rajkot, Gujarat, India
| | - Riddhi H Shukla
- School of Pharmaceutical Sciences, Atmiya University, Rajkot, Gujarat, India
| | - Prakruti R Buch
- Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India
| | - Jigna M Vadalia
- Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar, Gujarat, India
| | - Tejas P Sharma
- Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India
| | - Vishal A Airao
- Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India
| |
Collapse
|
2
|
Patel RD, Raval MK. Differential scanning calorimetry: A screening tool for the development of diacerein eutectics. RESULTS IN CHEMISTRY 2022. [DOI: 10.1016/j.rechem.2022.100315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Baxi K, Majmundar D, Patel A, Chandibhamar V, Patel N, Majmundar V. Diacerein in the treatment of chronic plaque psoriasis: A case report. INDIAN JOURNAL OF DRUGS IN DERMATOLOGY 2022. [DOI: 10.4103/ijdd.ijdd_19_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
|
4
|
Fouad SA, Malaak FA, El-Nabarawi MA, Abu Zeid K, Ghoneim AM. Preparation of solid dispersion systems for enhanced dissolution of poorly water soluble diacerein: In-vitro evaluation, optimization and physiologically based pharmacokinetic modeling. PLoS One 2021; 16:e0245482. [PMID: 33471832 PMCID: PMC7816977 DOI: 10.1371/journal.pone.0245482] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 01/02/2021] [Indexed: 01/09/2023] Open
Abstract
Diacerein (DCN), a BCS II compound, suffers from poor aqueous solubility and limited bioavailability. Solid dispersion systems (SD) of DCN were prepared by solvent evaporation, using hydrophilic polymers. In-vitro dissolution studies were performed and dissolution parameters were evaluated. I-Optimal factorial design was employed to study the effect of formulation variables (drug:polymer ratio and polymer type) on the measured responses including; drug content (DC) (%), dissolution efficiency at 15 min (DE (15 min)%) and 60 min (DE (60 min)%) and mean dissolution time (MDT) (min). The optimized SD was selected, prepared and evaluated, allowing 10.83 and 3.42 fold increase in DE (15 min)%, DE (60 min)%, respectively and 6.07 decrease in MDT, compared to plain drug. DSC, XRD analysis and SEM micrographs confirmed complete amorphization of DCN within the optimized SD. Physiologically based pharmacokinetic (PBPK) modeling was employed to predict PK parameters of DCN in middle aged healthy adults and geriatrics. Simcyp® software established in-vivo plasma concentration time curves of the optimized SD, compared to plain DCN. Relative bioavailability of the optimized SD compared to plain drug was 229.52% and 262.02% in healthy adults and geriatrics, respectively. Our study reports the utility of PBPK modeling for formulation development of BCS II APIs, via predicting their oral bio-performance.
Collapse
Affiliation(s)
- Shahinaze A. Fouad
- Department of Pharmaceutics, Faculty of Pharmacy, Ahram Canadian University, 6 of October City, Giza, Egypt
- * E-mail:
| | - Fady A. Malaak
- Department of Pharmaceutics, Faculty of Pharmacy, Ahram Canadian University, 6 of October City, Giza, Egypt
| | - Mohamed A. El-Nabarawi
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Khalid Abu Zeid
- Department of Pharmaceutics, Faculty of Pharmacy, Ahram Canadian University, 6 of October City, Giza, Egypt
| | - Amira M. Ghoneim
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt
| |
Collapse
|
5
|
Kaur D, Kaur J, Kamal SS. Diacerein, its beneficial impact on chondrocytes and notable new clinical applications. BRAZ J PHARM SCI 2018. [DOI: 10.1590/s2175-97902018000417534] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
6
|
The anthraquinone drug rhein potently interferes with organic anion transporter-mediated renal elimination. Biochem Pharmacol 2013; 86:991-6. [DOI: 10.1016/j.bcp.2013.08.016] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 08/12/2013] [Accepted: 08/13/2013] [Indexed: 01/08/2023]
|
7
|
Layek B, Kumar TS, Trivedi RK, Mullangi R, Srinivas NR. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of rhein in human plasma: application to a pharmacokinetic study. Biomed Chromatogr 2008; 22:616-24. [PMID: 18254155 DOI: 10.1002/bmc.977] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A highly sensitive and specific LC-MS/MS method has been developed and validated for the estimation of rhein with 100 microL human plasma using celecoxib as an internal standard (IS). The API-4,000 Q-Trap LC-MS/MS was operated under multiple reaction-monitoring mode using the electrospray ionization technique. The assay procedure involved extraction of rhein and IS from human plasma with acetonitrile, which yielded consistent recoveries of 36.01 and 65.85% for rhein and IS, respectively. The total chromatographic run time was 5.0 min and the elution of rhein and IS occurred at approximately 1.60 and 3.96 min, respectively. The resolution of peaks was achieved with 0.01 m ammonium acetate (pH 6.0):acetonitrile:methanol (30:58:12, v/v) on an Inertsil ODS-3 column. The method was proved to be accurate and precise at a linearity range of 0.005-5.00 microg/mL with a correlation coefficient (r) of >or=0.995. The lower limit of quantitation was 0.005 microg/mL. The intra- and inter-day precision and accuracy values were found to be within the assay variability limits as per the FDA guidelines. Rhein was found to be stable in the battery of stability studies. The application of the assay to pre-clinical pharmacokinetic studies confirmed the utility of the assay to derive pharmacokinetic parameters.
Collapse
Affiliation(s)
- Buddhadev Layek
- Drug Metabolism and Pharmacokinetics, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad-500 049, India
| | | | | | | | | |
Collapse
|
8
|
Steinmeyer J, Konttinen YT. Oral treatment options for degenerative joint disease--presence and future. Adv Drug Deliv Rev 2006; 58:168-211. [PMID: 16616797 DOI: 10.1016/j.addr.2006.01.007] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2005] [Accepted: 01/30/2006] [Indexed: 10/24/2022]
Abstract
Alleviation of pain and inhibition of inflammation are the primary goals of pharmacotherapy of osteoarthritis (OA). These therapeutic goals can almost always be accomplished by the use of analgesics and nonsteroidal anti-inflammatory drugs (NSAID). One of the main problems of NSAIDs is their gastrointestinal toxicity, for which a prophylactic medication should be considered particularly amongst risk groups. Recent studies have shown that COX-2-selective and maybe also non-selective NSAIDs increase the cardiovascular risk so that their application is getting now drastically restricted. Pharmacological results published until now suggest that a clinically relevant minor analgesic and/or anti-inflammatory effect can be attained with the use of some of the SYmptomatic Slow Acting Drugs in OA (SYSADOAs). However, no clinical studies exist, which can positively confirm prevention, slowing down or reversal of any advanced joint cartilage destruction by any individual medication. Disease modifying therapy is still in its infancy; discovery and development of novel therapeutic targets and agents are an extremely difficult task, currently challenging many pharmaceutical companies and academic institutions.
Collapse
Affiliation(s)
- Jürgen Steinmeyer
- Clinic and Policlinic of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg GmbH, Paul-Meimberg-Strasse 3, D-35385 Giessen, Germany.
| | | |
Collapse
|
9
|
Abstract
Diacerein is a drug for the treatment of patients with osteoarthritis. This drug is administered orally as 50 mg twice daily. Diacerein is entirely converted into rhein before reaching the systemic circulation. Rhein itself is either eliminated by the renal route (20%) or conjugated in the liver to rhein glucuronide (60%) and rhein sulfate (20%); these metabolites are mainly eliminated by the kidney. The pharmacokinetics characteristics of diacerein are about the same in young healthy volunteers and elderly people with normal renal function, both after a single dose (50 mg) or repeated doses (25 to 75 mg twice daily). Rhein kinetics after single oral doses of diacerein are linear in the range 50 to 200 mg. However, rhein kinetics are time-dependent, since the nonrenal clearance decreases with repeated doses. This results in a moderate increase in maximum plasma concentration, area under the plasma concentration-time curve and elimination half-life. Nevertheless, the steady-state is reached by the third administration and the mean elimination half-life is then around 7 to 8 hours. Taking diacerein with a standard meal delays systemic absorption, but is associated with a 25% increase in the amount absorbed. Mild-to-severe (Child Pugh's grade B to C) liver cirrhosis does not change the kinetics of diacerein, whereas mild-to-severe renal insufficiency (creatinine clearance < 2.4 L/h) is followed by accumulation of rhein which justifies a 50% reduction of the standard daily dosage. Rhein is highly bound to plasma proteins (about 99%), but this binding is not saturable so that no drug interactions are likely to occur, in contrast to those widely reported with nonsteroidal anti-inflammatory drugs. Except for moderate and transient digestive disturbances (soft stools, diarrhoea), diacerein is well tolerated and seems neither responsible for gastrointestinal bleeding nor for renal, liver or haematological toxicity.
Collapse
Affiliation(s)
- P Nicolas
- Département de Pharmacologie-Toxicologie Biologique, CHU Avicenne, Université Paris XIII, Bobigny, France
| | | | | | | |
Collapse
|
10
|
Abstract
Rhein, the active metabolite of diacerein, inhibits interleukin-1 activity. Consequently, collagenase production in articular cartilage is reduced. Rhein dose-dependently inhibits superoxide anion production, chemotaxis and phagocytic activity of neutrophils, and macrophage migration and phagocytosis. Articular cartilage damage is reduced by diacerein in animal models of osteoarthritis. Diacerein does not alter renal or platelet cyclooxygenase activity and may therefore be tolerated by patients with prostaglandin-dependent renal function. In clinical trials of < or = 6 months' duration, oral diacerein 50mg twice daily was associated with improvement in 57 to 85% of patients with osteoarthritis. Pain scores and measures of joint function were generally reduced compared with baseline and placebo. Diacerein had similar efficacy to NSAIDs, but a slower onset of action, in comparative trials of < or = 2 months' duration conducted in patients with osteoarthritis. The predominant adverse effects of diacerein are diarrhoea and related disorders.
Collapse
Affiliation(s)
- C M Spencer
- Adis International Limited, Auckland, New Zealand.
| | | |
Collapse
|